Emerging therapies in castration resistant prostate cancer
Related Experiment Video
Updated: Apr 30, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Gregory R Thoreson1, Bishoy A Gayed, Paul H Chung
1University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA.
Introduction:
Prostate cancer continues to be the second leading cause of cancer related mortality in men within the United States. Despite a consistent decline in prostate cancer mortality over the past two decades, the prognosis for men with metastatic prostate cancer remains poor with no curative therapies. In this article, we review the recently approved and emerging therapeutics for patients with castrate resistant prostate cancer.
Materials And Methods:
An advanced search was conducted on the clinicaltrials.gov database, using search terms "metastatic prostate cancer", and limiting results to phase II-IV clinical trials. Clinically relevant emerging therapeutics were selected and a Medline search for supporting documents was performed. An emphasis was placed on newly approved and promising new therapeutics.
Results:
A total of four Food and Drug Administration approved medications and eight investigational agents were chosen for review. The background and role of these therapeutics in the treatment of prostate cancer treatment is discussed.
Conclusions:
The past few years have yielded a near exponential increase in treatments for metastatic prostate cancer, many of which have a unique mechanism of action. The estimated median survival for patients with metastatic prostate cancer remains dynamic as we begin to integrate these therapeutics into clinical practice and determine the optimal sequence and timing of treatment.
Insights
Recent advances offer new hope for metastatic prostate cancer patients. This review covers approved and emerging treatments, aiming to improve outcomes for castrate-resistant disease.
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- Prostate cancer remains a significant cause of mortality in men.
- Metastatic prostate cancer has a poor prognosis with limited curative options.
- Castrate-resistant prostate cancer presents unique treatment challenges.
Purpose of the Study:
- To review recently approved and emerging therapeutics for metastatic prostate cancer.
- To discuss the role and background of these new treatments.
- To provide an overview of current and future therapeutic strategies.
Main Methods:
- Conducted an advanced search on clinicaltrials.gov for phase II-IV trials.
- Selected clinically relevant emerging therapeutics.
- Performed Medline searches for supporting literature, focusing on new agents.
Main Results:
- Identified four FDA-approved medications for review.
- Selected eight investigational agents for discussion.
- Detailed the background and therapeutic role of these agents.
Conclusions:
- A rapid increase in novel treatments for metastatic prostate cancer has occurred.
- Many new therapies possess unique mechanisms of action.
- Optimal sequencing and timing of these treatments are crucial for survival outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...